HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hitoshi Tsuda Selected Research

Clear Cell Adenocarcinoma

6/2012ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas.
1/2012PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
8/2011Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
11/2009Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.
4/2009Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.
2/2008Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.
7/2007Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.
7/2002Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hitoshi Tsuda Research Topics

Disease

178Neoplasms (Cancer)
12/2022 - 01/2002
100Breast Neoplasms (Breast Cancer)
07/2022 - 01/2002
41Carcinoma (Carcinomatosis)
12/2022 - 01/2002
30Neoplasm Metastasis (Metastasis)
01/2022 - 05/2002
26Adenocarcinoma
01/2021 - 04/2002
17Lymphatic Metastasis
07/2021 - 06/2005
15Ovarian Neoplasms (Ovarian Cancer)
08/2021 - 05/2006
12Colorectal Neoplasms (Colorectal Cancer)
10/2020 - 02/2005
11Carcinogenesis
06/2017 - 12/2005
8Triple Negative Breast Neoplasms
11/2020 - 01/2009
8Stomach Neoplasms (Stomach Cancer)
08/2014 - 02/2005
8Clear Cell Adenocarcinoma
06/2012 - 07/2002
7Endometrial Neoplasms (Endometrial Cancer)
04/2022 - 07/2007
7Endometriosis
05/2020 - 07/2007
7Ductal Carcinoma
03/2019 - 05/2005
7Squamous Cell Carcinoma of Head and Neck
03/2016 - 06/2005
7Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2014 - 05/2002
7Adenocarcinoma of Lung
09/2012 - 07/2007
6Lung Neoplasms (Lung Cancer)
10/2014 - 12/2007
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2014 - 07/2007
5Noninfiltrating Intraductal Carcinoma (DCIS)
01/2022 - 05/2005
5Ovarian Epithelial Carcinoma
09/2021 - 07/2002
5Adenoma (Adenomas)
06/2013 - 04/2002
4Seminoma
12/2021 - 09/2010
4Mucinous Adenocarcinoma (Mucinous Carcinoma)
02/2021 - 07/2002
4Endometrioid Carcinoma
10/2020 - 07/2002
4Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
06/2013 - 10/2011
3Prostatic Neoplasms (Prostate Cancer)
01/2022 - 02/2016
3Esophageal Squamous Cell Carcinoma
06/2017 - 03/2011
3Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
02/2014 - 09/2010
3Pathologic Complete Response
02/2013 - 01/2006

Drug/Important Bio-Agent (IBA)

59Proteins (Proteins, Gene)FDA Link
12/2022 - 06/2002
33Hormones (Hormone)IBA
11/2020 - 01/2002
23Biomarkers (Surrogate Marker)IBA
11/2021 - 05/2007
22ErbB Receptors (EGF Receptor)IBA
01/2020 - 12/2003
21Estrogen ReceptorsIBA
01/2022 - 01/2008
16Progesterone Receptors (Progesterone Receptor)IBA
01/2022 - 01/2008
16Phenobarbital (Luminal)FDA Link
01/2022 - 06/2005
16Messenger RNA (mRNA)IBA
01/2022 - 03/2002
16Biological ProductsIBA
10/2020 - 01/2002
15Formaldehyde (Formol)FDA Link
04/2022 - 12/2003
15DNA (Deoxyribonucleic Acid)IBA
03/2014 - 06/2002
14human ERBB2 proteinIBA
01/2022 - 08/2009
12ParaffinIBA
04/2022 - 12/2003
12Indicators and Reagents (Reagents)IBA
01/2022 - 05/2002
9Phosphotransferases (Kinase)IBA
09/2018 - 07/2006
9Trastuzumab (Herceptin)FDA Link
08/2014 - 01/2006
8Nucleic AcidsIBA
01/2022 - 08/2007
8Paclitaxel (Taxol)FDA LinkGeneric
09/2021 - 05/2006
7TamoxifenFDA LinkGeneric
03/2014 - 10/2007
6Pharmaceutical PreparationsIBA
11/2021 - 09/2002
6Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/2021 - 01/2005
6PlatinumIBA
01/2021 - 12/2006
6taxaneIBA
01/2020 - 07/2009
6Anaplastic Lymphoma KinaseIBA
09/2013 - 10/2011
5Keratin-19 (Keratin 19)IBA
01/2022 - 08/2007
5MesothelinIBA
10/2021 - 03/2019
5Fluorouracil (Carac)FDA LinkGeneric
02/2021 - 01/2005
5Cisplatin (Platino)FDA LinkGeneric
01/2021 - 05/2006
5Docetaxel (Taxotere)FDA Link
02/2012 - 01/2005
4SteroidsIBA
01/2022 - 01/2011
4Eosine Yellowish-(YS) (Eosin)IBA
03/2021 - 07/2010
4AnthracyclinesIBA
01/2020 - 08/2009
4AntigensIBA
01/2015 - 04/2006
4EnzymesIBA
02/2014 - 10/2007
4Estrogens (Estrogen)FDA Link
12/2013 - 01/2011
3LigandsIBA
12/2022 - 02/2008
3Protein Isoforms (Isoforms)IBA
12/2021 - 12/2007
3Carboplatin (JM8)FDA LinkGeneric
09/2021 - 08/2007
3UracilIBA
02/2021 - 10/2007
3TegafurIBA
02/2021 - 10/2007
3Amino Acid Transport Systems (Amino Acid Transporter)IBA
01/2021 - 06/2019
3Growth Factor ReceptorsIBA
11/2020 - 07/2004
3Membrane Glycoproteins (Membrane Glycoprotein)IBA
10/2020 - 03/2019
3Calcibiotic Root Canal SealerIBA
09/2020 - 02/2005
3Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
11/2019 - 04/2008
3ActininIBA
01/2014 - 12/2007
3Complementary DNA (cDNA)IBA
12/2013 - 05/2006
3Rituximab (Mabthera)FDA Link
11/2013 - 10/2012
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
06/2013 - 11/2003
3ProteomeIBA
01/2013 - 05/2011
3Cyclin AIBA
11/2012 - 11/2009
3Cyclin EIBA
11/2012 - 11/2009
3ProgesteroneFDA LinkGeneric
08/2012 - 01/2011
3Therapeutic UsesIBA
04/2012 - 07/2009
3Epirubicin (Ellence)FDA LinkGeneric
02/2012 - 01/2005
3AntibodiesIBA
11/2011 - 07/2011

Therapy/Procedure

53Therapeutics
01/2022 - 06/2002
34Drug Therapy (Chemotherapy)
01/2022 - 01/2002
24Neoadjuvant Therapy
01/2020 - 01/2002
9Adjuvant Chemotherapy
07/2022 - 12/2006
8Segmental Mastectomy (Lumpectomy)
01/2022 - 03/2002
7Radiotherapy
01/2022 - 05/2002
7Lasers (Laser)
01/2016 - 04/2002
6Lymph Node Excision (Lymph Node Dissection)
05/2017 - 05/2002
4Mastectomy (Mammectomy)
08/2019 - 01/2011
4Hysterectomy
10/2012 - 05/2002
4Radiofrequency Ablation
01/2011 - 01/2011
3Radical Mastectomy
03/2019 - 01/2011
3Modified Radical Mastectomy (Mastectomy, Modified)
03/2019 - 10/2006